Home › Funds › Tetragon Partners GP Ltd › AGIO
Tetragon Partners GP Ltd position in AGIO
AGIOS PHARMACEUTICALS INC · Health Care
Tetragon Partners GP Ltd reported holding 50,000 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.9M, representing 0.30% of its reported portfolio and ranking #32 among its reported holdings. Tetragon Partners GP Ltd has disclosed AGIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tetragon Partners GP Ltd's AGIO position evolved
Tetragon Partners GP Ltd first disclosed a stake in AGIO in Q4 2025 at 162,018 shares (US$4.4M). The position peaked in Q1 2026 at 164,839 shares, worth US$5.6M. Across 3 filings, Tetragon Partners GP Ltd increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 50,000 shares valued at US$1.9M — a reduction of -114,839 shares quarter over quarter.. Notable position changes include a 70% trim in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2025 | 162.02K | $4.41M | New |
| Q1 2026 | 164.84K | $5.58M | Add |
| Q2 2026 | 50.00K | $1.86M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGIO and 13F data
AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 31 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$219.6M), Lynx1 Capital Management LP (US$126.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGIO
- Farallon Capital Management 5.92M sh · $219.59M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 5.92M sh · $219.59M · Q2 2026
- Lynx1 Capital Management LP 3.41M sh · $126.51M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.40M sh · $89.06M · Q2 2026
- Erste Asset Management GmbH 2.15M sh · $81.97M · Q2 2026
- ADAR1 Capital Management, LLC 1.29M sh · $47.80M · Q2 2026
- Foresite Capital Management VI LLC 785.00K sh · $29.13M · Q2 2026
- Parkman Healthcare Partners LLC 669.05K sh · $24.83M · Q2 2026
More on Tetragon Partners GP Ltd
FAQ
How long has Tetragon Partners GP Ltd held AGIO?
Tetragon Partners GP Ltd has disclosed AGIO holdings in 3 of the last 3 reported quarters, going back to Q4 2025.
What is Tetragon Partners GP Ltd's current position in AGIO?
As of Q2 2026, Tetragon Partners GP Ltd holds 50.00K shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $1.86M, representing 0.30% of its reported portfolio and ranking #32.
Has Tetragon Partners GP Ltd been buying or selling AGIO?
In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd reduced its position in AGIO. The position peaked in Q1 2026 at 164.84K shares.
Which other funds hold AGIO?
Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Lynx1 Capital Management LP, among 31 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.